Document Detail


One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk.
MedLine Citation:
PMID:  20609697     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Beta-blockers have played a key role in the management of hypertension-related cardiovascular disease for decades, and continue to be recommended as a mainstay of therapy in national guidelines statements. Recent data have shown less optimal reductions in total mortality, CVD mortality, and CVD events with beta-blockers compared with renin-angiotensin system-blocking agents or calcium channel blockers. The beta-blocker class, however, spans a wide range of agents, and the growing concern about the risk-benefit profile of beta-blockers should not be generalized to later-generation vasodilating beta-blockers such as carvedilol and nebivolol. A growing database from hypertension studies confirms the clinical efficacy and safety of vasodilating beta-blockers, and outcome studies indicate that these agents can play an important role in global CVD reduction in patients with hypertensive or ischemic heart failure.
Authors:
Jan N Basile
Related Documents :
1071677 - Clinical trial of the beta-adrenoreceptor-blocking agent tolamolol with the use of 24 h...
6206327 - A comparison of the hemodynamic effects of prenalterol and isoprenaline in patients wit...
6764167 - Effects of propranolol and atenolol on plasma renin activity and systolic time interval...
16750737 - The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during symp...
10893107 - Central sleep apnea and chronic heart failure.
966177 - Energetics of isovolumic contractions of the isolated rabbit heart.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  123     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-08     Completed Date:  2010-08-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S9-15     Citation Subset:  AIM; IM    
Copyright Information:
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Affiliation:
College of Medicine, Medical University of South Carolina and Ralph H Johnson VA Medical Center, Charleston, South Carolina 29425-0950, USA. basilejn@musc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology,  therapeutic use*
Benzopyrans / therapeutic use
Ethanolamines / therapeutic use
Humans
Hypertension / physiopathology,  prevention & control*
Risk Assessment
Stroke / physiopathology,  prevention & control*
Vasodilator Agents / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Ethanolamines; 0/Vasodilator Agents; 99200-09-6/nebivolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of vasodilating beta-blockers in patients with hypertension and the cardiometabolic syndrom...
Next Document:  Aspiration of immature oocytes during cesarean section for fertility preservation and future surroga...